EA201591618A1 - Замещенные имидазопиридазины - Google Patents

Замещенные имидазопиридазины

Info

Publication number
EA201591618A1
EA201591618A1 EA201591618A EA201591618A EA201591618A1 EA 201591618 A1 EA201591618 A1 EA 201591618A1 EA 201591618 A EA201591618 A EA 201591618A EA 201591618 A EA201591618 A EA 201591618A EA 201591618 A1 EA201591618 A1 EA 201591618A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
substituted
imidazopiridazines
pharmaceutical compositions
hyperproliferative
Prior art date
Application number
EA201591618A
Other languages
English (en)
Other versions
EA029027B1 (ru
Inventor
Маркус Коппитц
Ульрих Клар
Антье Маргрет Венгнер
Роланд Нойхаус
Герхард Зимайстер
Михаэль Брюнинг
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50179606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201591618A1 publication Critical patent/EA201591618A1/ru
Publication of EA029027B1 publication Critical patent/EA029027B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к соединениям замещенных имидазопиридазинов, к способам получения указанных соединений, к фармацевтическим композициям и комбинациям, содержащим указанные соединения, а также к применению указанных соединений для производства фармацевтических композиций для лечения или профилактики заболевания, в частности гиперпролиферативного и/или ангиогенного расстройства, в виде отдельного вещества или в комбинации с другими активными ингредиентами.
EA201591618A 2013-03-01 2014-02-25 Замещенные имидазопиридазины EA029027B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13157453 2013-03-01
EP13198930 2013-12-20
PCT/EP2014/053573 WO2014131739A2 (en) 2013-03-01 2014-02-25 Substituted imidazopyridazines

Publications (2)

Publication Number Publication Date
EA201591618A1 true EA201591618A1 (ru) 2016-02-29
EA029027B1 EA029027B1 (ru) 2018-01-31

Family

ID=50179606

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591618A EA029027B1 (ru) 2013-03-01 2014-02-25 Замещенные имидазопиридазины

Country Status (36)

Country Link
US (1) US9512130B2 (ru)
EP (1) EP2961752B1 (ru)
JP (1) JP2016511252A (ru)
KR (1) KR20150125654A (ru)
CN (1) CN105008364B (ru)
AP (1) AP2015008636A0 (ru)
AU (1) AU2014222806A1 (ru)
BR (1) BR112015020990A2 (ru)
CA (1) CA2902978A1 (ru)
CL (1) CL2015002433A1 (ru)
CR (1) CR20150455A (ru)
CU (1) CU20150094A7 (ru)
CY (1) CY1119667T1 (ru)
DK (1) DK2961752T3 (ru)
EA (1) EA029027B1 (ru)
ES (1) ES2651765T3 (ru)
GT (1) GT201500247A (ru)
HK (1) HK1213876A1 (ru)
HR (1) HRP20171890T1 (ru)
HU (1) HUE037417T2 (ru)
IL (1) IL240348A0 (ru)
LT (1) LT2961752T (ru)
MX (1) MX2015011316A (ru)
NI (1) NI201500118A (ru)
NO (1) NO2961752T3 (ru)
PE (1) PE20151759A1 (ru)
PH (1) PH12015501913A1 (ru)
PL (1) PL2961752T3 (ru)
PT (1) PT2961752T (ru)
RS (1) RS56665B1 (ru)
SG (1) SG11201505882QA (ru)
SI (1) SI2961752T1 (ru)
TN (1) TN2015000371A1 (ru)
TW (1) TW201437211A (ru)
UY (1) UY35360A (ru)
WO (1) WO2014131739A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521740A (ja) * 2013-06-13 2016-07-25 バイエル・ファルマ・アクティエンゲゼルシャフト 癌を治療するためのイミダゾピリダジン誘導体と有糸分裂阻害剤の組合せ
TW201613927A (en) 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
CN107635586B (zh) 2014-12-15 2021-09-24 拜耳医药股份有限公司 Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
CA2990394A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
WO2019002542A1 (en) * 2017-06-30 2019-01-03 Les Laboratoires Servier COMBINATION OF AN INHIBITOR OF MPS1 AND A TAXANE COMPOUND, USES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
CN111377925B (zh) * 2018-12-28 2024-03-12 四川科伦博泰生物医药股份有限公司 嘌呤类衍生物、其制备方法及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3104759A1 (de) * 1981-02-11 1982-08-19 Bayer Ag, 5090 Leverkusen Dihalogenierte imidazolcarbonsaeure-amide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JP2830210B2 (ja) * 1989-11-17 1998-12-02 日本曹達株式会社 α，β―不飽和ケトン類の合成法
US6068834A (en) * 1994-03-04 2000-05-30 The Procter & Gamble Company Skin lightening compositions
FR2804955B1 (fr) * 2000-02-11 2003-02-14 Rhodia Chimie Sa Procede de fonctionnalisation d'une double liaison
CN101541801A (zh) * 2006-08-04 2009-09-23 武田药品工业株式会社 稠杂环衍生物及其用途
CN101981033B (zh) * 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
AU2011227511B2 (en) * 2010-03-15 2014-02-20 Amgen Inc. Spiro-tetracyclic ring compounds as Beta - secretase modulators
WO2011137155A1 (en) * 2010-04-28 2011-11-03 Bristol-Myers Squibb Company Imidazopyridazinyl compounds and their uses for cancer
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP2738170B1 (en) * 2011-07-29 2017-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014020041A1 (en) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer

Also Published As

Publication number Publication date
EP2961752A2 (en) 2016-01-06
HUE037417T2 (hu) 2018-08-28
UY35360A (es) 2014-09-30
TN2015000371A1 (en) 2017-01-03
HRP20171890T1 (hr) 2018-01-12
PE20151759A1 (es) 2015-12-20
EP2961752B1 (en) 2017-09-13
TW201437211A (zh) 2014-10-01
HK1213876A1 (zh) 2016-07-15
CY1119667T1 (el) 2018-04-04
LT2961752T (lt) 2017-12-27
BR112015020990A2 (pt) 2017-07-18
EA029027B1 (ru) 2018-01-31
CN105008364A (zh) 2015-10-28
PT2961752T (pt) 2017-12-18
NI201500118A (es) 2015-10-19
CL2015002433A1 (es) 2016-01-04
GT201500247A (es) 2017-10-05
US9512130B2 (en) 2016-12-06
SI2961752T1 (en) 2018-01-31
CR20150455A (es) 2015-10-26
CU20150094A7 (es) 2016-05-30
CA2902978A1 (en) 2014-09-04
SG11201505882QA (en) 2015-09-29
CN105008364B (zh) 2017-11-07
KR20150125654A (ko) 2015-11-09
WO2014131739A3 (en) 2014-12-04
RS56665B1 (sr) 2018-03-30
JP2016511252A (ja) 2016-04-14
IL240348A0 (en) 2015-09-24
PH12015501913A1 (en) 2016-01-04
NO2961752T3 (ru) 2018-02-10
AU2014222806A1 (en) 2015-09-03
PL2961752T3 (pl) 2018-02-28
WO2014131739A2 (en) 2014-09-04
DK2961752T3 (en) 2017-12-11
ES2651765T3 (es) 2018-01-29
US20160016959A1 (en) 2016-01-21
AP2015008636A0 (en) 2015-08-31
MX2015011316A (es) 2015-12-03

Similar Documents

Publication Publication Date Title
EA201591618A1 (ru) Замещенные имидазопиридазины
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201691881A1 (ru) Новые соединения
EA201690183A1 (ru) Замещенные пиразолопиридинамины
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201690930A1 (ru) Композиции и способы модуляции фарнезоидных х-рецепторов
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
PH12015502535B1 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
EA201600398A1 (ru) Тиенопиримидины в качестве ингибиторов mknk1 и mknk2
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA201590617A1 (ru) Композиции алкилированного циклодекстрина и способы их получения и применения
EA201592227A1 (ru) Стабильные растворы объединенных активных фармацевтических ингредиентов для перорального применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU